Haemonetics Corporation (HAE) Stock Price & How to Invest

Last updated November 2026

Short answer

Haemonetics (NYSE: HAE) is a blood and plasma technology company whose machines and single-use disposables collect plasma for the drug industry and manage blood inside hospitals. Buying it is a bet that the plasma business keeps growing, now with CSL Plasma, the largest customer it lost, saying in October 2026 that it expects to move all of its US collection centers back onto Haemonetics devices and disposables by the end of 2027, and that the acquired hospital devices earn their purchase price. As of October 16, 2026 the shares closed at ~$119.15, up ~49% year to date and ~139% over the past year.

HAE stock price

As of 2026-11-16, Haemonetics Corporation (HAE) last closed at $121.34, up 63.3% over the past year. Over the past 52 weeks it has traded between $52.24 and $127.42.

HAE last close
$121.34
1 day
-1.30%
1 month
+2.59%
1 year
+63.27%
52-week range
$52.24 to $127.42
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Haemonetics Corporation's investor relations page. Walnut is informational, not investment advice.

HAE key stats

At $121.34 on November 16, 2026, Haemonetics Corporation (HAE) has a market cap of $5.5B and a P/E of 53.7 on trailing earnings (19.5 on forward earnings). It next reports earnings around February 4, 2027 (estimated).

Market cap
$5.5B
P/E (trailing)
53.7
P/E (forward)
19.5
EPS (trailing 12 months)
$2.26
Price to book
6.1
Beta
0.59
Next earnings
around February 4, 2027 (estimated)

Market cap, P/E and yield are measured at the $121.34 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Haemonetics Corporation (HAE)?

The last two weeks for Haemonetics Corporation, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • HAE closed at $121.34 on November 16, 2026, up 2.6% over the past five trading days (from $118.21).
  • Haemonetics Corporation next reports quarterly results around February 4, 2027 (estimated).
  • On November 5, 2026, Haemonetics Corporation filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 5, 2026, Haemonetics Corporation filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 6, 2026, Citigroup raised its target to $149.00 from $123.00 (Buy).
  • On November 6, 2026, Barrington Research raised its target to $145.00 from $140.00 (Outperform).
  • On November 5, 2026, BTIG raised its target to $142.00 from $130.00 (Buy).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Haemonetics Corporation (HAE) latest quarter

Haemonetics reported revenue of $358 million for Q2 fiscal 2027, up 9% from a year earlier (Haemonetics, Nov 5, 2026).

Revenue
$358 million
up 9% from a year earlier
Diluted EPS (GAAP)
$1.00
up 23% from a year earlier
Apheresis
$205 million
up 13% from a year earlier

Source: Haemonetics Q2 fiscal 2027 results, Nov 5, 2026. Full earnings breakdown

What does Haemonetics Corporation (HAE) do?

Haemonetics Corporation, based in Boston and listed on the NYSE, has sold blood-handling technology since 1971. Its largest business is plasma: the NexSys PCS apheresis machines, and the far more profitable single-use disposable kits that run on them, sit in the collection centers operated by companies like Grifols, Takeda's BioLife and Octapharma, which turn donated plasma into immunoglobulin and other plasma-derived therapies. A second business, grouped under the hospital umbrella, splits into Interventional Technologies (the VASCADE and VASCADE MVP vascular closure devices used after catheter procedures, plus the OpSens optical pressure sensing line and the Attune Medical esophageal cooling device) and Blood Management Technologies (TEG viscoelastic hemostasis analyzers, Cell Saver autotransfusion systems, and blood-tracking software). A third and shrinking business supplies whole-blood and apheresis collection to blood banks.

The investment picture for the past several years was dominated by one contract. CSL Plasma, historically Haemonetics' single biggest plasma customer, chose not to renew and moved to a competing device, and the transitional supply that followed rolled off through fiscal 2025, leaving a revenue headwind in the roughly $70 million to $100 million range that suppressed reported growth into fiscal 2026. That comparison is now behind the company. In the quarter ended June 2026, the first of fiscal 2027, revenue was about $339 million, up roughly 6% on both a reported and organic basis, with plasma up about 8% organically and the hospital businesses up about 6%, and adjusted EPS of ~$1.14 beat the ~$1.08 consensus. Management raised the full-year outlook to roughly 5% to 8% reported growth.

Then the story turned. On October 8, 2026 Haemonetics disclosed in an SEC filing that CSL Plasma expects to complete a rollout of Haemonetics devices and disposables by the end of 2027, with all of CSL's US collection centers expected to transition, though the filing noted that scope and timing could change. The shares rose ~16% that day. Haemonetics left fiscal 2027 guidance unchanged and said it would describe the expected impact of the CSL supply agreement on its fiscal second-quarter call, scheduled for November 5, 2026, where analysts expect ~$345 million of revenue and ~$1.29 of adjusted EPS. At ~$119.15 a share and about $5.4 billion of market value against roughly $1.35 billion of trailing revenue, the market now pays about four times sales, and the question has shifted from "how durable is what is left" to "how much revenue does CSL bring back, and how fast".

What's driving Haemonetics Corporation (HAE)?

1. Plasma, and the return of CSL.

For the first time in several years, plasma revenue is being compared against a base that no longer contains the departed CSL volumes, and the June 2026 quarter's roughly 8% organic plasma growth was the first clean read on that base. The October 2026 disclosure changes the shape of the next two years: CSL expects all of its US plasma centers to move to Haemonetics products, with the rollout complete by the end of 2027. If that happens on that timeline, plasma growth would be driven by a large customer returning rather than by yield gains alone. Underlying collection demand is tied to immunoglobulin therapy, which has grown steadily as diagnosis rates rise, and switching devices means requalifying an entire center network, which is why a returning customer tends to stay. The financial terms have not yet been disclosed; management plans to address them in November.

2. Yield software as a razor-blade lever.

Persona and the Persona PLUS rollout adjust how much plasma is drawn from each donor within the FDA nomogram, so a center collects more liters from the same donor pool and the same floor space. That matters because the customer's cost per liter falls while Haemonetics sells more disposables per visit. It is a way to grow revenue inside existing accounts rather than by winning new ones, which is the harder task in a market with few remaining buyers.

3. Interventional technologies after the ablation reset.

VASCADE MVP is used to close femoral access sites after cardiac ablation, and the rapid 2025 shift toward pulsed field ablation disrupted procedure mix and slowed that franchise. Management described the electrophysiology market as stabilizing in the June 2026 quarter, with interventional technologies returning to growth. The OpSens SavvyWire in structural heart and the Attune esophageal cooling device sit alongside it, and together these acquisitions represent roughly a billion dollars of capital that has yet to be fully validated by growth.

4. Hospital blood management as the steady leg.

TEG hemostasis analyzers and Cell Saver autotransfusion are installed-base businesses with recurring cartridge and bowl consumption, tied to surgical volumes rather than to any single therapy cycle. They grow in the mid single digits without much drama and fund the noisier parts of the portfolio. Blood management and vascular closure together drove the roughly 6% hospital growth reported for the June 2026 quarter.

What are the risks to Haemonetics Corporation (HAE)?

Customer concentration is the structural risk, and the CSL news cuts both ways: plasma collection in the United States is consolidated into a handful of buyers, the original CSL departure showed how much revenue a single non-renewal can remove, and the stock's ~139% one-year gain now assumes a CSL rollout whose scope and timing the company itself says could change. Pricing and ramp costs on that agreement are unknown until the November 5 call. Immunoglobulin demand has been reliable but is not guaranteed, and any move by a large customer toward in-house or competing collection hardware would repeat the problem. The interventional portfolio was assembled through three acquisitions in roughly two years, which leaves goodwill and intangibles on the balance sheet and about $1.17 billion of debt against them, and the pulsed field ablation transition has already demonstrated that a procedure-mix shift can cut into those products faster than the thesis assumed. The blood center business continues to decline as hospitals use less transfused blood, so mix has to keep improving just to hold consolidated growth flat. Tariffs, medical-device quality regulation and the pace of hospital capital budgets are the usual additional constraints on a company that manufactures physical disposables at scale.

What is the Haemonetics Corporation (HAE) forecast?

10 analysts publish price targets on HAE, averaging $142.10 as of November 2026, or +17.1% against the $121.34 share price on November 16, 2026. The published targets run from $115.00 to $165.00, a moderate spread, and the ratings split 9 buy, 2 hold, 0 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full HAE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is HAE a buy or a sell?

We give no verdict on Haemonetics Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Plasma, and the return of CSL. For the first time in several years, plasma revenue is being compared against a base that no longer contains the departed CSL volumes, and the June 2026 quarter's roughly 8% organic plasma growth was the first clean read on that base. The most optimistic published target, $165.00, assumes this works close to its best case.

The case against. Customer concentration is the structural risk, and the CSL news cuts both ways: plasma collection in the United States is consolidated into a handful of buyers, the original CSL departure showed how much revenue a single non-renewal can remove, and the stock's ~139% one-year gain now assumes a CSL rollout whose scope and timing the company itself says could change. The most pessimistic target, $115.00, is roughly what HAE is worth if this bites instead.

Read the full bull and bear case on HAE, including what would have to change to break either one. Walnut is not an investment adviser.

Has Haemonetics Corporation (HAE) split its stock?

No. Haemonetics Corporation (HAE) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Haemonetics Corporation (HAE) valued?

Market cap, P/E and dividend yield at today's price are in the HAE key stats above. The business figures below come from Haemonetics Corporation's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$1.35B, up ~6% in the latest quarter
  • Q1 FY2027 revenue (quarter ended June 2026): ~$339M, up ~6% organic; adj. EPS ~$1.14 vs ~$1.08 est.
  • Net income (TTM): ~$96M; operating margin ~18%
  • Price / TTM sales: ~4.0x
  • FY2027 revenue growth guidance: ~5% to 8% reported (unchanged after CSL news)

As of October 2026: The multiple has re-rated from a little over three times sales in August to about four times, and from roughly the mid-teens to ~21x forward earnings, almost entirely on the CSL disclosure. Trailing GAAP EPS of ~$2.06 is held down by charges, including a loss in the March 2026 quarter, while analysts expect ~$5.31 of adjusted EPS for fiscal 2027 and ~$5.78 for fiscal 2028. The price now reflects a returning customer that has not yet shown up in revenue or guidance, which makes the November 5 call the next real test.

Who competes with Haemonetics Corporation (HAE)?

Plasma and blood collection systems

Terumo BCT is the direct competitor, and its Rika system is what CSL moved to, which is the clearest possible demonstration that these accounts can be lost. Fresenius Kabi competes with the Aurora platform, and Grifols runs meaningful collection capability in-house. The installed base is sticky because requalifying devices across hundreds of centers is expensive, but the buyer list is short enough that each contract cycle is material.

Vascular closure and interventional cardiology

VASCADE competes against Abbott's Perclose and StarClose, Teleflex's MANTA, Cordis and Terumo in femoral access closure, all of which sell into the same catheterization labs through broader cardiovascular bags. In pressure sensing and structural heart, the OpSens products face Abbott, Boston Scientific and Philips. Haemonetics is a specialist here competing against companies with far larger hospital sales organizations.

Hospital hemostasis and blood management

TEG's main rival is Werfen, whose ROTEM viscoelastic platform serves the same operating rooms and trauma bays. Cell Saver autotransfusion competes with LivaNova, Fresenius and Medtronic. These are slow-moving installed-base markets where the analyzer placement, not the individual test, determines share for years afterward.

What stocks are similar to Haemonetics Corporation (HAE)?

Other names that sit close to HAE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Haemonetics Corporation (HAE)

There are three common ways to get HAE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so HAE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where HAE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Haemonetics Corporation (HAE)

HAE has gone from a niche medical-device name priced for slow growth to one priced for a recovery: CSL's planned return roughly doubled the stock over a year and lifted it to ~21x forward earnings, so the case now rests on that rollout arriving on schedule and on the interventional acquisitions delivering the growth they were bought for.

More on Haemonetics Corporation (HAE)

Whether HAE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HAE a buy or a sell?, and where the stock could go from here in the HAE stock forecast.

For income investors, whether HAE pays a dividend and how the payout looks is covered in does HAE pay a dividend? And to weigh HAE against a peer, read the full side-by-side comparisons: HAE vs CSL and HAE vs GRFS.

Wondering how HAE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Haemonetics Corporation

Ask Walnut's AI anything about HAE and see how it fits what you own.

FAQ

What does Haemonetics actually sell?

+

Machines and, more importantly, the single-use disposable kits that run on them. Plasma collection devices sit in donation centers, and hospital products include vascular closure devices, hemostasis analyzers and autotransfusion systems. The recurring disposable revenue, not the hardware, is where most of the margin comes from.

What was the CSL contract and why did it matter so much?

+

CSL Plasma was Haemonetics' largest plasma customer. It chose not to renew its supply agreement and moved to a competing collection device, with transitional supply running off through fiscal 2025. The revenue removed was in the roughly $70 million to $100 million range, which suppressed reported growth for two fiscal years. Fiscal 2027 is the first year comparing against a base without it. In October 2026 the relationship reversed: Haemonetics disclosed that CSL expects to transition all of its US plasma centers back to Haemonetics devices and disposables, completing the rollout by the end of 2027.

Is plasma growing again?

+

In the quarter ended June 2026, plasma revenue grew about 8% organically, and total company revenue reached about $339 million, up roughly 6%. That is the first clean quarter without CSL distorting the comparison. Whether mid to high single digits persists depends on immunoglobulin demand and on the Persona PLUS yield rollout at existing customers.

What is VASCADE and what happened to it?

+

VASCADE and VASCADE MVP are vascular closure devices used to seal femoral access sites after catheter procedures, acquired with Cardiva Medical in 2021. The rapid shift to pulsed field ablation in electrophysiology during 2025 changed procedure mix and slowed the franchise. Management described the market as stabilizing and the business as back to growth in the June 2026 quarter.

How is HAE valued relative to its revenue?

+

At roughly $5.4 billion of market value against about $1.35 billion of trailing revenue, the shares trade near four times sales as of October 2026, up from about three times in August. The rerating followed the CSL disclosure, and the forward P/E is now ~21x against analysts' fiscal 2028 EPS estimate of ~$5.78.

What is guidance for fiscal 2027?

+

After the August 2026 report, management raised the full-year outlook to roughly 5% to 8% reported revenue growth and roughly 4% to 7% organic growth. The raise followed a quarter in which plasma, blood management and vascular closure all contributed, rather than growth resting on one line. Guidance was left unchanged after the October 2026 CSL disclosure; management said it would update investors on the CSL agreement's expected impact on the fiscal second-quarter call on November 5, 2026.

What are the main risks to the story?

+

Customer concentration is the largest, since a small number of plasma collectors control most of the addressable volume and the CSL loss showed what one non-renewal costs. Beyond that: procedure-mix shifts in electrophysiology, the integration and payback on roughly a billion dollars of interventional acquisitions plus the debt behind them, and the continuing secular decline of the blood center business.

How would a thematic investor hold HAE?

+

It usually appears as a specialist medical-device or plasma-supply-chain position rather than a standalone holding, since its fortunes track immunoglobulin demand and a handful of collection contracts more than broad healthcare. In Walnut you can add it to a basket alongside other device and diagnostics names, write down why the plasma recovery matters to your thesis, and watch how it moves against the rest of the group.

Is CSL Plasma coming back to Haemonetics?

+

According to an October 8, 2026 SEC filing, yes: CSL Plasma expects to complete a rollout of Haemonetics devices and disposables by the end of 2027 and expects all of its US collection centers to transition. The filing cautioned that scope and timing could change, and the financial terms were not disclosed. Shares rose ~16% on the day of the announcement.

How has HAE stock performed in 2026?

+

As of October 16, 2026, HAE closed at ~$119.15, up ~49% year to date, ~53% over three months and ~139% over the past year, near the top of a 52-week range of ~$48.98 to ~$123.77. The 10 analysts covering it have an average target of ~$124.50 and a consensus buy rating, and Barrington raised its target to $140 in October. Walnut is not an investment adviser; this describes past performance, not a forecast.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Haemonetics Corporation's investor relations page or your broker before making investment decisions.